Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957721 · ClinicalTrials.gov registry record · NA
Diabetes Engagement and Activation Platform
A NA study of Type 2 Diabetes (T2D), sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT02957721 is a NA study of Type 2 Diabetes (T2D) that has completed, run by Virginia Commonwealth University. The registered enrollment target is 350 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02957721, a NA study of Type 2 Diabetes (T2D), has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The following are hypothesized: 1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary care workflow to facilitate the care of patients with type 2 diabetes. 2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes. 3. The DEAP intervention will enhance patient activation and improve type 2 diabetes self management and glucose control
Conditions Studied
Interventions
- OTHER Usual Care
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-11-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02957721
The ClinicalTrials.gov registry entry for NCT02957721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes (T2D) appearing as the primary indexed condition, and to 1 intervention - of which Usual Care is the first listed.
NCT02957721 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT02957721 about?
NCT02957721 is a clinical study titled "Diabetes Engagement and Activation Platform". The following are hypothesized: 1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary care workflow to facilitate the care of patients with type 2 diabetes. 2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes. 3. The DEAP inte...
What is the current status of trial NCT02957721?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2017-11-01. Estimated completion is 2018-11-05.
What conditions does trial NCT02957721 study?
This clinical trial studies the following conditions: Type 2 Diabetes (T2D).
What interventions are being tested in trial NCT02957721?
The interventions under investigation include: Usual Care (OTHER).
Who is sponsoring clinical trial NCT02957721?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02957721 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.